GRAIL (NASDAQ:GRAL) Stock Price Up 6.9% – Still a Buy?

Posted by Geri Gentry on Sep 24th, 2026

Shares of GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) were up 6.9% on Thursday . The company traded as high as $113.09 and last traded at $115.9690. Approximately 510,514 shares were traded during trading, a decline of 46% from the average daily volume of 948,330 shares. The stock had previously closed at $108.52.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

Positive Sentiment: FDA advisers backed Galleri’s safety and narrowly supported the evidence for its effectiveness. Although the efficacy vote was not decisive, the recommendation improves the test’s prospects for premarket approval. FDA advisers back safety of Grail’s cancer test
Positive Sentiment: The advisory-panel vote brings Galleri closer to a final FDA ruling. Approval could expand GRAIL’s commercial opportunity and provide significant validation for its technology. GRAIL’s Multi-Cancer Blood Test Gets FDA Committee Vote
Positive Sentiment: GRAIL reported findings from its PATHFINDER 2 study, adding clinical data for investors evaluating Galleri’s potential ahead of the FDA decision. GRAIL Reports PATHFINDER 2 Study Findings
Positive Sentiment: Robert W. Baird raised its price target to $118 from $96 and maintained an “outperform” rating, citing improved confidence in Galleri’s regulatory outlook.
Positive Sentiment: Institutional ownership trends were supportive: State Street increased its GRAIL position by 26.1% in the second quarter, while several other institutions also added shares.
Neutral Sentiment: Trading was temporarily halted ahead of the FDA advisory meeting, underscoring the importance of the announcement and contributing to elevated volatility. GRAIL Trading Halted Ahead of FDA AdCom Meeting
Negative Sentiment: Goldman Sachs initiated coverage with a “hold” rating, suggesting the recent rally may already reflect much of the near-term opportunity.
Negative Sentiment: CEO Joshua Ofman sold 61,452 shares and CFO Aaron Freidin sold 4,100 shares under pre-arranged Rule 10b5-1 plans. The planned nature reduces the warning signal, but the insider selling may weigh modestly on sentiment.
Negative Sentiment: Analyst sentiment remains mixed, with an average rating of “hold” and a consensus target of $75.10, below recent trading levels. GRAIL also remains unprofitable, with analysts forecasting a full-year loss.

Analyst Ratings Changes

Several research analysts have recently issued reports on GRAL shares. TD Cowen restated a “buy” rating on shares of GRAIL in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Royal Bank Of Canada began coverage on shares of GRAIL in a research report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 price target for the company. The Goldman Sachs Group began coverage on GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective on the stock. Finally, UBS Group set a $84.00 target price on GRAIL in a report on Thursday, September 17th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $75.10.

Check Out Our Latest Stock Report on GRAL

GRAIL Trading Up 3.3%

The business’s fifty day moving average price is $76.27 and its 200 day moving average price is $64.72. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of -11.50 and a beta of 3.25.

GRAIL (NASDAQ:GRAL – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The firm had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. As a group, sell-side analysts forecast that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Insider Transactions at GRAIL

In other news, CEO Joshua Ofman sold 61,452 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the sale, the chief executive officer owned 362,271 shares in the company, valued at approximately $35,408,367.54. This represents a 14.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 4,100 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $93.34, for a total value of $382,694.00. Following the transaction, the chief financial officer directly owned 248,983 shares in the company, valued at approximately $23,240,073.22. This represents a 1.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 78,452 shares of company stock valued at $7,485,691 over the last ninety days. Corporate insiders own 1.83% of the company’s stock.

Institutional Trading of GRAIL

A number of hedge funds have recently added to or reduced their stakes in GRAL. BlackRock Inc. lifted its holdings in shares of GRAIL by 20.5% during the second quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock worth $244,207,000 after purchasing an additional 608,539 shares during the period. State Street Corp grew its position in GRAIL by 26.1% in the 2nd quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after buying an additional 493,621 shares during the last quarter. Primecap Management Co. CA acquired a new position in GRAIL in the 2nd quarter valued at $148,836,000. Baker BROS. Advisors LP increased its stake in GRAIL by 27.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after buying an additional 455,208 shares during the period. Finally, Bank of America Corp DE raised its position in GRAIL by 29.0% during the 1st quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock worth $47,241,000 after buying an additional 205,611 shares during the last quarter.

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.